Publications

Uronis, H. E., K. Bullock, G. Blobe, S. Hsu, M. Morse, A. Nixon, S. Haley, M. O’Neill, H. Hurwitz, and J. Bendell. “A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e15506.

PMID
27962236
Scholars@Duke

Bullock, K. E., H. I. Hurwitz, H. E. Uronis, M. A. Morse, G. C. Blobe, S. D. Hsu, S. Y. Zafar, A. B. Nixon, L. A. Howard, and J. C. Bendell. “Bevacizumab (B) plus everolimus (E) in refractory metastatic colorectal cancer (mCRC).” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 4080.

PMID
27961646
Scholars@Duke

Sathornsumetee, S., A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, H. S. Friedman, and D. A. Reardon. “Phase II study of bevacizumab plus erlotinib for recurrent malignant gliomas.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.

Scholars@Duke

Starodub, A., J. Jia, S. Cushman, D. Marshall, H. I. Hurwitz, and A. B. Nixon. “Dual inhibition of αV integrins and Src kinase activity in colon cancer cells.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): e14609.

PMID
27964163
Scholars@Duke

Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.

Scholars@Duke

Stinchcombe, T. E., L. Hodgson, J. E. Herndon, M. J. Kelley, M. Cicchetti, N. Ramnath, H. B. Niell, J. N. Atkins, M. R. Green, and E. E. Vokes. “Clinical factors predictive of overall survival (OS) and the identification of prognostic groups in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy on Cancer and Leukemia and Group B trial (CALGB) 39801.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.

Scholars@Duke

Sampson, J. H., G. E. Archer, D. D. Bigner, R. J. Schmittling, J. E. Herndon, T. Davis, H. S. Friedman, T. Keler, D. A. Reardon, and D. A. Mitchell. “Effect of daclizumab on T-Reg counts and EGFRvIII-specific immune responses in GBM.” In Journal of Clinical Oncology, Vol. 27. AMER SOC CLINICAL ONCOLOGY, 2009.

Scholars@Duke

Howard, L. A., K. E. Bullock, J. C. Bendell, H. E. Uronis, G. Vlahovic, G. C. Blobe, R. F. Riedel, A. B. Nixon, J. P. Gockerman, and H. I. Hurwitz. “Bevacizumab (B) plus everolimus (E) and panitumumab (P) in refractory advanced solid tumors.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 3551.

PMID
27961368
Scholars@Duke

Abernethy, A. P., S. Y. Zafar, R. Coeytaux, K. Rowe, J. L. Wheeler, and H. K. Lyerly. “Electronic patient-reported data capture as the foundation of a learning health care system.” J Clin Oncol 27, no. 15_suppl (May 20, 2009): 6522.

PMID
27964028
Scholars@Duke

Kondo, S., E. M. Sturgis, F. Li, Q. Wei, and G. Li. “GSTM1 and GSTT1 null polymorphisms and risk of salivary gland carcinoma.” International Journal of Clinical and Experimental Medicine 2, no. 1 (May 19, 2009): 68–75.

Scholars@Duke

Pages